Currently, there are 62.54M common shares owned by the public and among those 55.09M shares have been available to trade.
The company’s stock has a 5-day price change of 33.19% and 13.09% over the past three months. SAGE shares are trading 67.03% year to date (YTD), with the 12-month market performance down to -16.41% lower. It has a 12-month low price of $4.62 and touched a high of $13.47 over the same period. SAGE has an average intraday trading volume of 968.09K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 33.01%, 29.52%, and 31.64% respectively.
Institutional ownership of Sage Therapeutics Inc (NASDAQ: SAGE) shares accounts for 85.56% of the company’s 62.54M shares outstanding.
It has a market capitalization of $567.97M and a beta (3y monthly) value of 0.17. The earnings-per-share (ttm) stands at -$5.80. Price movements for the stock have been influenced by the stock’s volatility, which stands at 15.99% over the week and 7.14% over the month.
Earnings per share for the fiscal year are expected to increase by 46.38%, and 22.23% over the next financial year. EPS should grow at an annualized rate of 35.78% over the next five years, compared to 13.20% over the past 5-year period.
Looking at the support for the SAGE, a number of firms have released research notes about the stock. BofA Securities stated their Underperform rating for the stock in a research note on March 11, 2025, with the firm’s price target at $5. RBC Capital Mkts coverage for the Sage Therapeutics Inc (SAGE) stock in a research note released on November 21, 2024 offered a Sector Perform rating with a price target of $4. Raymond James was of a view on October 10, 2024 that the stock is Mkt Perform, while RBC Capital Mkts gave the stock Sector Perform rating on October 04, 2024, issuing a price target of $10- $4. TD Cowen on their part issued Hold rating on July 30, 2024.
